Asset sale Announced Sponsor buyer

Subsidiary of Piramal Pharma acquisition of Worldwide rights to Kenalog

US$35m consideration

Announced 8 Apr 2026

Advisers

Worldwide rights to Kenalog

Target

Not disclosed

Target
Worldwide rights to Kenalog
Acquirer
Subsidiary of Piramal Pharma
Sponsor
Piramal Pharma
Seller
Bristol-Myers Squibb
Buyer based in
India (unverified)
Seller based in
United States
Sector
Pharma

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.